C.R. Bard, Inc. (NYSE:BCR) is expected to pay $0.26 on Nov 4, 2016. The indicated annual dividend is $1.04. Shareholders owning the stock before Oct 20, 2016 will be eligible to receive the payout. Based on C.R. Bard, Inc.’s current price of $223.42, the dividend is 0.12%. This dividend’s record date is Oct 24, 2016 and the announcement date is Oct 12, 2016. The stock increased 2.00% or $4.38 during the last trading session, hitting $223.42. C R Bard Inc (NYSE:BCR) has risen 15.08% since March 16, 2016 and is uptrending. It has outperformed by 9.53% the S&P500.
C. R. Bard, Inc. and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company has a market cap of $16.35 billion. The Firm sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities. It has a 44.13 P/E ratio. It operates through the manufacturing and sale of medical devices segment.
Insitutional Activity: The institutional sentiment decreased to 0.88 in Q2 2016. Its down 0.07, from 0.95 in 2016Q1. The ratio worsened, as 42 funds sold all C R Bard Inc shares owned while 222 reduced positions. 50 funds bought stakes while 182 increased positions. They now own 63.71 million shares or 9.15% less from 70.13 million shares in 2016Q1.
Raymond James & owns 9,552 shares or 0.01% of their US portfolio. Moreover, Fil Ltd has 0.01% invested in C R Bard Inc (NYSE:BCR) for 12,237 shares. Checchi Advisers Ltd Liability Corp has 740 shares for 0.02% of their US portfolio. Farmers has 17,765 shares for 1.36% of their US portfolio. Next Fin Gru accumulated 0% or 50 shares. Ashfield Limited Liability last reported 38,737 shares in the company. Goldman Sachs Group Inc Inc accumulated 0.1% or 1.29 million shares. Nicholas Invest Partners L P owns 13,430 shares or 0.22% of their US portfolio. Moreover, Valley National Advisers has 2.04% invested in C R Bard Inc (NYSE:BCR) for 16,687 shares. Lynch And Associate In last reported 2,000 shares in the company. Independent Port Consultants Incorporated holds 0% of its portfolio in C R Bard Inc (NYSE:BCR) for 65 shares. Main Street Rech Ltd reported 43,443 shares or 2.11% of all its holdings. Sva Plumb Wealth Limited Liability Company holds 1,000 shares or 0.04% of its portfolio. Standard Life Limited accumulated 1.03 million shares or 1.09% of the stock. Glenmede Na, a Pennsylvania-based fund reported 74,423 shares.
Insider Transactions: Since April 27, 2016, the stock had 0 buys, and 9 insider sales for $29.42 million net activity. 10,000 shares were sold by Luboff Sharon M, worth $2.10M. RING TIMOTHY M also sold $21.03 million worth of C R Bard Inc (NYSE:BCR) on Tuesday, September 27. Shares for $1.01M were sold by Beasley Jim C on Thursday, April 28. $1.75M worth of C R Bard Inc (NYSE:BCR) was sold by DeFord John A. Thompson Tommy G sold $109,760 worth of stock. Another trade for 3,970 shares valued at $872,945 was sold by HOLLAND CHRISTOPHER S. 9,183 shares were sold by Khichi Samrat S., worth $2.03 million.
C R Bard Inc (NYSE:BCR) Ratings Coverage
Out of 11 analysts covering CR Bard (NYSE:BCR), 4 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 36% are positive. $265 is the highest target while $190 is the lowest. The $224.13 average target is 0.32% above today’s ($223.42) stock price. CR Bard has been the topic of 16 analyst reports since August 27, 2015 according to StockzIntelligence Inc. On Wednesday, July 27 the stock rating was maintained by Barclays Capital with “Equalweight”. Nomura initiated C R Bard Inc (NYSE:BCR) on Thursday, March 17 with “Neutral” rating. As per Friday, September 16, the company rating was upgraded by Wells Fargo. The rating was initiated by Evercore on Thursday, September 15 with “Buy”. Bank of America downgraded C R Bard Inc (NYSE:BCR) on Friday, July 8 to “Neutral” rating. Goldman Sachs upgraded C R Bard Inc (NYSE:BCR) rating on Thursday, August 27. Goldman Sachs has “Neutral” rating and $220 price target. The firm earned “Buy” rating on Thursday, November 12 by Citigroup. The stock has “Sector Weight” rating given by KeyBanc Capital Markets on Thursday, August 27. On Wednesday, July 27 the stock rating was maintained by Jefferies with “Hold”. Citigroup maintained C R Bard Inc (NYSE:BCR) rating on Wednesday, July 27. Citigroup has “Buy” rating and $265 price target.
More recent C R Bard Inc (NYSE:BCR) news were published by: Finance.Yahoo.com which released: “C.r. Bard Inc (BCR) Chairman and CEO Timothy M Ring Sold $25.2 million of Shares” on September 28, 2016. Also Nasdaq.com published the news titled: “C.r. Bard Inc (BCR) Chairman and CEO Timothy M Ring Sold $â€”5.â€” million of Shares” on September 28, 2016. Gurufocus.com‘s news article titled: “Timothy Ring, CEO and Chairman of C.R. Bard Inc., Sold 9â€”,â€”9’ Shares of the …” with publication date: October 01, 2016 was also an interesting one.
BCR Company Profile
C. R. Bard, Inc. (Bard), incorporated in 1923, and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Firm operates through the manufacture and sale of medical devices segment. The Firm sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. The Firm reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Firm also has a product group of other products. Through its subsidiaries, the Company markets its products to clients in over 100 countries outside the United States. The Company’s principal international markets are in Europe, Japan and China.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.